Galectin-3 in heart failure with preserved ejection fraction (Q38104695)

28 August 2017

title

Galectin-3 in heart failure with preserved ejection fraction (English)

1 reference

Heart failure with preserved ejection fraction

28 August 2017

0 references

1 reference

1 reference

Alain Cohen-Solal

1 reference

28 August 2017

Burkert Pieske

1 reference

28 August 2017

Rudolf A de Boer

1 reference

28 August 2017

Frank Edelmann

series ordinal

1 reference

28 August 2017

Mamas A Mamas

series ordinal

1 reference

28 August 2017

Alan Maisel

series ordinal

1 reference

28 August 2017

language of work or name

1 reference

5 May 2013

1 reference

European Journal of Heart Failure

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

1095-1101

1 reference

Trends in prevalence and outcome of heart failure with preserved ejection fraction

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Death in heart failure: a community perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3: a novel mediator of heart failure development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

What mechanisms underlie diastolic dysfunction in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Aldosterone inhibits antifibrotic factors in mouse hypertensive heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

The fibrosis marker galectin-3 and outcome in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Role of advanced glycation end products in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Epidemiology and risk profile of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3 in heart failure: more answers or more questions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Exploring the role of galectin 3 in kidney function: a genetic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

Diastolic Stiffness of the Failing Diabetic Heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT077

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFT077

1 reference

28 August 2017

1 reference